Azacitidine
- Generic Name
- Azacitidine
- Brand Names
- Onureg, Vidaza, Azacitidine Accord, Azacitidine betapharm, Azacitidine Mylan, Azacitidine Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N4O5
- CAS Number
- 320-67-2
- Unique Ingredient Identifier
- M801H13NRU
- Background
Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity. Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. As an analogue of cytidine, it is able to incorporate into ...
- Indication
Azacitidine (for subcutaneous or intravenous use) is indicated for the treatment of adult patients with the following French-American-British (FAB) myelodysplastic syndrome (MDS) subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemi...
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Refractory Anemia, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Excess of Blasts (RAEB), Refractory Anemia With Ringed Sideroblasts, Newly diagnosed Juvenile Myelomonocytic Leukaemias (JMML)
- Associated Therapies
- -
Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Uma Borate
- Target Recruit Count
- 53
- Registration Number
- NCT05379166
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants
- Conditions
- Interventions
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT05367401
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
- Conditions
- Interventions
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT05365035
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma
- First Posted Date
- 2022-05-02
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT05355051
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Demethylating Agent Azacitidine on Prevention of Acute Kidney Injury-chronic Kidney Disease Continuum
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2022-05-06
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT05325099
- Locations
- 🇨🇳
Yu Hsiang Chou, Taipei City, Taiwan
5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC
- Conditions
- Interventions
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Barbara Burtness
- Target Recruit Count
- 50
- Registration Number
- NCT05317000
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
Venetoclax Basket Trial for High Risk Hematologic Malignancies
- Conditions
- Myelodysplastic Syndromes, SecondaryMyelodysplastic Syndromes, Previously TreatedTreatment-Related Acute Myeloid LeukemiaTherapy-Related Myelodysplastic SyndromeAcute Lymphoblastic Leukemia With Failed RemissionMyelodysplastic Syndromes, de NovoLymphoblastic Lymphoma, in RelapseAcute Leukemia of Ambiguous Lineage in RelapseLymphoblastic Lymphoma, RefractoryAcute Leukemia of Ambiguous Lineage
- Interventions
- First Posted Date
- 2022-03-23
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Andrew E. Place, MD
- Target Recruit Count
- 92
- Registration Number
- NCT05292664
- Locations
- 🇺🇸
University of California San Francisco-Benioff Children's Hospital, San Francisco, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse
- First Posted Date
- 2022-03-08
- Last Posted Date
- 2022-09-14
- Lead Sponsor
- Zhujiang Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05270200
- Locations
- 🇨🇳
Nanfang Hospital of Southern Medical University, Guanzhou, Guandong, China
Microtransplantation Combined With Azacytidine to Improve the Efficacy of EAML
- Conditions
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- guomei
- Target Recruit Count
- 300
- Registration Number
- NCT05262465
- Locations
- 🇨🇳
The fifth medical center of PLA General Hospital, Beijing, Beijing, China
AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2022-01-27
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- AB Science
- Target Recruit Count
- 78
- Registration Number
- NCT05211570
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇪🇸Clínica Universidad de Navarra, Pamplona, Spain
🇬🇷National and Kapodistrian University of Athens NKUA · Department of Hematology and Bone marrow Transplantation Unit, Athens, Greece
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.